0.395
Precedente Chiudi:
$0.3351
Aprire:
$0.3331
Volume 24 ore:
414.77K
Relative Volume:
2.48
Capitalizzazione di mercato:
$20.01M
Reddito:
-
Utile/perdita netta:
$-68.80M
Rapporto P/E:
-0.3376
EPS:
-1.17
Flusso di cassa netto:
$-59.06M
1 W Prestazione:
+22.67%
1M Prestazione:
+1.02%
6M Prestazione:
-37.24%
1 anno Prestazione:
-70.52%
Passage Bio Inc Stock (PASG) Company Profile
Nome
Passage Bio Inc
Settore
Industria
Telefono
(267) 866-0312
Indirizzo
ONE COMMERCE SQUARE, PHILADELPHIA, PA
Confronta PASG con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
PASG
Passage Bio Inc
|
0.395 | 20.01M | 0 | -68.80M | -59.06M | -1.17 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
501.15 | 126.96B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
605.61 | 65.06B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
649.67 | 37.54B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
259.39 | 32.56B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
255.77 | 26.40B | 3.81B | -644.79M | -669.77M | -6.24 |
Passage Bio Inc Stock (PASG) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2024-11-29 | Ripresa | Wedbush | Outperform |
2024-09-03 | Iniziato | Rodman & Renshaw | Buy |
2022-03-08 | Downgrade | JP Morgan | Overweight → Neutral |
2022-01-19 | Downgrade | Goldman | Buy → Neutral |
2021-07-01 | Iniziato | Raymond James | Outperform |
2021-06-15 | Iniziato | BTIG Research | Buy |
2021-03-04 | Aggiornamento | Goldman | Neutral → Buy |
2021-02-04 | Iniziato | Guggenheim | Buy |
2021-01-25 | Iniziato | Wedbush | Outperform |
2021-01-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
2020-12-11 | Iniziato | Citigroup | Neutral |
2020-08-14 | Downgrade | JP Morgan | Overweight → Neutral |
2020-06-25 | Downgrade | Goldman | Buy → Neutral |
2020-03-25 | Iniziato | Chardan Capital Markets | Buy |
2020-03-24 | Iniziato | Cowen | Outperform |
2020-03-24 | Iniziato | Goldman | Buy |
2020-03-24 | Iniziato | JP Morgan | Overweight |
Mostra tutto
Passage Bio Inc Borsa (PASG) Ultime notizie
Orbimed Advisors LLC Reduces Stake in Passage Bio Inc: A Strategic Portfolio Adjustment - GuruFocus
Fierce Biotech Layoff Tracker 2025: Entrada cuts 20% of workforce; Ono lays off 83 staffers - Fierce Biotech
Orbimed advisors sells Passage Bio stock for $49,704 - Investing.com Australia
Orbimed advisors sells Passage Bio stock for $49,704 By Investing.com - Investing.com Canada
Analyzing Agenus (NASDAQ:AGEN) & Passage Bio (NASDAQ:PASG) - Defense World
PASG stock touches 52-week low at $0.3 amid market challenges - Investing.com Australia
Frontotemporal Dementia Pipeline 2025: Key Companies, MOA, - openPR.com
GM1 Gangliosidosis Treatment Market: Advances & Emerging - openPR.com
Passage Bio stock plunges to 52-week low of $0.35 By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.35 - Investing.com
Layoff Tracker: BioAtla Streamlines Operations By Cutting 30% of Staff - BioSpace
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
Krabbe Disease Treatment Market is to grow at a 7.22 % CAGR, with the United States leading the market through 2032 - StreetInsider.com
Strategic Partnership To Advance Gene Therapies For Rare Diseases: Key Trend in The GM1 Gangliosidosis Glob... - WhaTech
Annovis Bio Reports Progress in Clinical Trials and Improved Financial Position - MyChesCo
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Third Arc Bio Enters Clinical Stage with First Patient Dosed in ARC101 Study - MyChesCo
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges - Investing.com Australia
Passage Bio stock plunges to 52-week low of $0.38 amid market challenges By Investing.com - Investing.com South Africa
Annovis Bio to Showcase Advancements at Alzheimer’s & Parkinson’s Drug Development Summit - MyChesCo
Passage Bio Reports 2024 Financial Results and Advances in PBFT02 Program - MSN
Wedbush Comments on Passage Bio’s Q1 Earnings (NASDAQ:PASG) - Defense World
Passage Bio (PASG) Upgraded to Buy: Here's What You Should Know - Nasdaq
FY2029 Earnings Forecast for Passage Bio Issued By Wedbush - Defense World
Chardan Cuts Price Target on Passage Bio to $6 From $7, Keeps Buy Rating -March 05, 2025 at 07:36 am EST - Marketscreener.com
Passage Bio (NASDAQ:PASG) Price Target Lowered to $6.00 at Chardan Capital - Defense World
Passage Bio Advances Gene Therapy for Neurodegenerative Diseases - TipRanks
Strategic Restructuring and Promising Data Catalysts Drive Buy Rating for Passage Bio - TipRanks
Chardan cuts Passage Bio stock price target to $6, maintains buy - Investing.com India
Chardan cuts Passage Bio stock price target to $6, maintains buy By Investing.com - Investing.com South Africa
Passage Bio stock plunges to 52-week low of $0.45 - Investing.com India
Passage Bio stock plunges to 52-week low of $0.45 By Investing.com - Investing.com South Africa
Passage Bio Inc Azioni (PASG) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):